News

Tokyo, Japan., Dec 26, 2013  – REGiMMUNE Corporation (RGI) today announced that the Company has appointed Mr. Kenzo Kosuda to the position of senior vice president, chief financial officer (CFO), and a member of the board effective as of Today.  Mr. Kosuda has spent the over 20 years in various CFO positions for companies including Sparx [...]

Santa Clara, CA and TOKYO — April 12, 2013 — REGiMMUNE Corporation., a privately held biopharmaceutical company, announced today that it has appointed Mr. Nakamura, Dr. Misawa, Dr. Matsuishi and Mr.Hirai the as non-executive director. Mr. Nakamura is currently the head at one of the venture investment sections and a member of the fund planning [...]

RGI-2001 has been granted Orphan Drug Designation for RGI-2001 from FDA Tokyo, Japan-(OCT. 28, 2012) – REGiMMUNE Corporation announced today that RGI-2001, the company’s liposomal formulation of alpha-GalCer, has been granted Orphan Drug Designation by the U.S. Food & Drug Administration (FDA) for the treatment of Graft-versus-Host Disease (GvHD) associated with hematopoietic stem cell transplantation. [...]

Tokyo, Japan-(OCT. 28, 2012) – REGiMMUNE Corporation announced today that RGI-2001, the company’s liposomal formulation of alpha-GalCer, has been granted Orphan Drug Designation by the U.S. Food & Drug Administration (FDA) for the treatment of Graft-versus-Host Disease (GvHD) associated with hematopoietic stem cell transplantation. Orphan Drug Designation is a special status granted by FDA to [...]

Second Tranche of Private Placement Announced REGiMMUNE announced the closing of the second tranche of a Preferred A financing. The company closed $0.5 million U.S. in the second tranche of previously announced financing (1/30/2012). In this tranche, Chibagin Capital (www.chibagincapital.co.jp) joined as an investor. Chibagin Capital is a VC arm of Chiba bank, which is the [...]

REGiMMUNE Corporation announced today that it has appointed Mr. Kohtaro Toda as a board member. He is currently an investment manager of Japan Asia Investment Co., Ltd. (JAIC), a Japanese venture capital firm with $1 billion under management. The addition of this new management position reflects the company’s continued progress into a clinical stage company, [...]

Tokyo, Japan – January 31, 2012 (US time)– REGiMMUNE Corporation said today that it has begun a Phase I/II study of its proprietary compound RGI-2001 for Graft versus Host Disease (GvHD) associated with hematopoietic stem cell transplantation. The safety and efficacy study will enroll approximately 50 bone marrow or peripheral blood stem cell transplantation leukemia [...]

Basis patent for the target specific tolerance induction by GalCer liposome, reVax technology, has been granted Tokyo, JAPAN–(Nov 28, 2011) – REGiMMUNE Corp. (“Company”) announces that the Japanese Patent Office has granted a patent, containing claims for a target specific tolerance induction technology, which we named reVax technology. The issued patent covers the GalCer liposome [...]

REGiMMUNE Corp. Announces Publication of preclinical GvHD data Tokyo, JAPAN–(Nov 22, 2010) – REGiMMUNE Corp. (“Company”) is pleased to announce the acceptance and publication of the paper entitled “Pharmacological Expansion of Donor-derived, Naturally Occurring CD4+Foxp3+ Regulatory T Cells Reduces Acute GvHD Lethality without Abrogating GvL in Murine Models.” by the Biology of Blood and Marrow Transplantation(in [...]

REGiMMUNE Presents New ToleroVax Data at the 2010 American Transplant Congress San Diego, CA – May 4, 2010 – REGiMMUNE Corporation said today that data from a preclinical study showed an enhanced immune suppression when ToleroVax (RGI-2001), its lead product candidate for the prevention of acute Graft-versus-Host Disease (GvHD), is combined with anti-thymocyte globulin (ATG). [...]

About Press release from RIKEN regarding RGI-1001

Tokyo, Japan –Sep. 1, 2006 – REGiMMUNE Corporation, a privately held biopharmaceutical company, announced that it has entered into a license agreement with RIKEN. Under the agreement, an exclusive right to market/sublicense pharmaceutical products based on RIKEN’s immune regulating technology is granted to REGiMMUNE from RIKEN. For Information Contact: Yuko Amizaki, Director, Corporate Planning REGiMMUNE. [...]

KRN7000, a synthetic derivative of alpha-galactosylceramide, is a small molecule that potently activates natural killer T (NKT) cells. RGI-2001 is a proprietary liposomal formulation of KRN7000. RGI-2001 has shown to induce antigen-specific immune suppression by inducing regulatory T cells (Tregs). Tregs are believed to play a central role in inducing and maintaining immune tolerance. RGI-2001 [...]

Tokyo, Japan and Mountain View, CA – July 22, 2009 – REGiMMUNE Corporation today announced that Astellas Pharma Inc. and REGiMMUNE have entered into a collaboration agreement to jointly research and develop a novel vaccine-platform technology. The partnership will combine Astellas’ broad range of capabilities in screening and developing natural source-derived compounds with REGiMMUNE’s immune liposome [...]

Boston, MA – June 1, 2009 – REGiMMUNE Corporation today announced that its lead product candidate RGI-2001, in combination with a low-dose of Sirolimus, demonstrated enhanced efficacy in transplantation tolerance induction in models of skin transplantation and acute Graft-versus-Host disease (GvHD). This data is being presented today in a poster titled “Donor-Specific Tolerance Induction by [...]